Objective To explore the efficacy and adverse drug reactions of albuvirtide(ABT)in the treatment of patients with acquired immunodeficiency syndrome(AIDS).Methods A total of 92 patients with AIDS admitted to Suzhou Fifth People's Hospital from May 2021 to May 2023 were selected.Drug efficacy and risk factors were analysed.Results The baseline HIV RNA of 92 patients was 5.3(5.0,6.4)Log10 copies/ml,of which the mean HIV RNA of 84 patients tested at 40 d of treatment was 2.4(1.0,3.9)Log10 copies/ml.Compared with the baseline,there was a decrease of 2.9 Log10 copies/ml,and difference was statistically significant(Z=0.872,P＜0.05).The other 8 patients had HIV RNA＞4.8 Log10 copies/ml.The baseline CD4+T-lymph count was(358±176)/μl,and after 40 d of treatment the CD4+T-lymph count was(443±187)/μl,and CD4+T-cell counts were all significantly increased.A total of 17 patients experienced adverse drug reactions,in which the incidence of common adverse reactions was 76％(13/17),important adverse reactions was 24％(4/17).The results of univariate analysis showed that smoking,CD4+,CD8+,decreased hemoglobin,decreased white blood cells,anemia,and a his-tory of drug allergy had a statistically significant impact on the occurrence of adverse reactions(P＜0.05);and mul-tifactorial analysis showed that smoking,leukopenia,a history of drug allergy and anaemia were independent risk factors for distinguishing the occurrence of the occurrence of adverse reactions.Conclusion ABT for AIDS can reduce the replication rate of HIV RNA and improve the immune function,a history of drug allergy and smok-ing,leukopenia and anaemia are independent risk factors for adverse reactions.
Acquired immunedeficiency syndromeEboweteDrug-related side effects and adverse re-actionsInfluencing factor
维普
万方数据
